The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.

Journal Section:
Editor's choice
Keywords:
Dopamine D<sub>2</sub> receptor supersensitivity, Schizophrenia, Antipsychotics, Drug-induced psychoses, Rebound, Antipsychotic-induced psychosis, Tardive dyskinesia, Supersensitivity psychosis, Dopamine supersensitivity psychosis
1.
Chouinard G, Chouinard VA: Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 2008;77:69-77.
[PubMed]
https://doi.org/10.1159/000112883
2.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
[PubMed]
https://doi.org/10.1056/NEJMoa051688
3.
Seeman P: Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10:515-531.
[PubMed]
https://doi.org/10.1517/14728222.10.4.515
4.
Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K: Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 2013;33:398-404.
[PubMed]
https://doi.org/10.1097/JCP.0b013e31828ea95c
5.
Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007;68(suppl 14):27-30.
[PubMed]
6.
Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196:326-328.
[PubMed]
https://doi.org/10.1126/science.847477
7.
Creese I, Burt DR, Snyder SH: Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 1977;197:596-598.
[PubMed]
https://doi.org/10.1126/science.877576
8.
Charron A, Hage CE, Servonnet A, Samaha AN: 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur Neuropsychopharmacol 2015;25:2381-2393.
[PubMed]
https://doi.org/10.1016/j.euroneuro.2015.10.002
9.
Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S: Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008;64:145-152.
[PubMed]
https://doi.org/10.1016/j.biopsych.2008.01.010
10.
Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007;27:2979-2986.
[PubMed]
https://doi.org/10.1523/JNEUROSCI.5416-06.2007
11.
Bedard AM, Maheux J, Levesque D, Samaha AN: Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 2011;36:1248-1259.
[PubMed]
https://doi.org/10.1038/npp.2011.10
12.
Bedard AM, Maheux J, Levesque D, Samaha AN: Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophr Bull 2013;39:692-702.
[PubMed]
https://doi.org/10.1093/schbul/sbs077
13.
El Hage C, Bedard AM, Samaha AN: Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology 2015;99:715-725.
[PubMed]
https://doi.org/10.1016/j.neuropharm.2015.03.012
14.
Chouinard G: Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5:21-33.
[PubMed]
https://doi.org/10.1016/0920-9964(91)90050-2
15.
Kirkpatrick B, Alphs L, Buchanan RW: The concept of supersensitivity psychosis. J Nerv Ment Dis 1992;180:265-270.
[PubMed]
16.
Seeman MV, Seeman P: Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry 2014;48:155-160.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2013.10.003
17.
Seeman P: Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 2013;23:999-1009.
[PubMed]
https://doi.org/10.1016/j.euroneuro.2013.06.005
18.
Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P: Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-180.
[PubMed]
19.
Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B: High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry 1982;17:849-852.
[PubMed]
20.
Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L-DOPA-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-738.
[PubMed]
https://doi.org/10.1016/0006-3223(93)90044-E
21.
Chouinard G, Jones BD: Schizophrenia as dopamine-deficiency disease. Lancet 1978;2:99-100.
[PubMed]
22.
Chouinard G, Jones BD: Evidence of brain dopamine deficiency in schizophrenia. Can J Psychiatry 1979;24:661-667.
[PubMed]
23.
Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994;91:11651-11654.
[PubMed]
24.
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104-8109.
[PubMed]
https://doi.org/10.1073/pnas.97.14.8104
25.
Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T: Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 2005;102:3513-3518.
[PubMed]
https://doi.org/10.1073/pnas.0409766102
26.
Seeman P: All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther 2011;17:118-132.
[PubMed]
https://doi.org/10.1111/j.1755-5949.2010.00162.x
27.
George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P: The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985;117:690-697.
[PubMed]
https://doi.org/10.1210/endo-117-2-690
28.
Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135:1409-1410.
[PubMed]
29.
Davis KL, Rosenberg GS: Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 1979;14:699-703.
[PubMed]
30.
Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21.
[PubMed]
31.
Chouinard G: New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004;65:9S-15S.
[PubMed]
32.
Moncrieff J: Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Med Hypotheses 2006;67:517-523.
[PubMed]
https://doi.org/10.1016/j.mehy.2006.03.009
33.
Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006;114:3-13.
[PubMed]
https://doi.org/10.1111/j.1600-0447.2006.00787.x
34.
Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M: A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 2014;155:52-58.
[PubMed]
https://doi.org/10.1016/j.schres.2014.02.022
35.
Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M: Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res 2015;227:278-282.
[PubMed]
https://doi.org/10.1016/j.psychres.2015.02.021
36.
Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M: Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 2015;29:383-389.
[PubMed]
https://doi.org/10.1177/0269881115570083
37.
Fallon P, Dursun SM: A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 2011;25:755-762.
[PubMed]
https://doi.org/10.1177/0269881109359097
38.
Fallon P, Dursun S, Deakin B: Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol 2012;2:13-22.
[PubMed]
https://doi.org/10.1177/2045125311431105
39.
Margolese HC, Chouinard G, Beauclair L, Belanger MC: Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002;22:347-352.
[PubMed]
https://doi.org/10.1097/00004714-200208000-00003
40.
Ekblom B, Eriksson K, Lindstrom LH: Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984;83:293-294.
[PubMed]
https://doi.org/10.1007/BF00464798
41.
Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015;84:63-71.
[PubMed]
https://doi.org/10.1159/000371865
42.
Sasaki H, Hashimoto K, Maeda Y, Inada T, Kitao Y, Fukui S, Iyo M: Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci 1995;56:PL443-PL447.
[PubMed]
https://doi.org/10.1016/0024-3205(95)00218-U
43.
Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M: Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur J Pharmacol 1995;282:71-76.
[PubMed]
https://doi.org/10.1016/0014-2999(95)00278-S
44.
Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M: Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull 2012;38:1012-1020.
[PubMed]
https://doi.org/10.1093/schbul/sbr006
45.
Lerer B, Jabotinsky-Rubin K, Bannet J, Ebstein RP, Belmaker RH: Electroconvulsive shock prevents dopamine receptor supersensitivity. Eur J Pharmacol 1982;80:131-134.
[PubMed]
https://doi.org/10.1016/0014-2999(82)90188-1
46.
Smith RC, Davis JM: Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci 1976;19:725-731.
[PubMed]
https://doi.org/10.1016/0024-3205(76)90170-3
47.
Turrone P, Remington G, Kapur S, Nobrega JN: The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003;165:166-171.
[PubMed]
https://doi.org/10.1007/s00213-002-1259-z
48.
O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990;6:146-153.
[PubMed]
https://doi.org/10.1002/syn.890060205
49.
Wilmot CA, Szczepanik AM: Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 1989;487:288-298.
[PubMed]
https://doi.org/10.1016/0006-8993(89)90833-0
50.
Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S: D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009;34:662-671.
[PubMed]
https://doi.org/10.1038/npp.2008.116
51.
Huang N, Ase AR, Hebert C, van Gelder NM, Reader TA: Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 1997;30:277-290.
[PubMed]
https://doi.org/10.1016/S0197-0186(96)00093-9
52.
Muller P, Seeman P: Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl) 1978;60:1-11.
[PubMed]
https://doi.org/10.1007/BF00429171
53.
Marin C, Chase TN: Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur J Pharmacol 1993;231:191-196.
[PubMed]
https://doi.org/10.1016/0014-2999(93)90448-Q
54.
Ase AR, Amdiss F, Hebert C, Huang N, van Gelder NM, Reader TA: Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm (Vienna) 1999;106:75-105.
[PubMed]
https://doi.org/10.1007/s007020050142
55.
Rivest R, Falardeau P, Di Paolo T: Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 1995;692:269-272.
[PubMed]
https://doi.org/10.1016/0006-8993(95)00611-S
56.
Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A: Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 2013;18:909-915.
[PubMed]
https://doi.org/10.1038/mp.2012.109
57.
Chesi AJ, Feasey-Truger KJ, Alzheimer C, ten Bruggencate G: Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: an in vivo and in vitro voltammetric study. Eur J Neurosci 1995;7:2450-2457.
[PubMed]
https://doi.org/10.1111/j.1460-9568.1995.tb01043.x
58.
Ichikawa J, Meltzer HY: The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 1992;574:98-104.
[PubMed]
https://doi.org/10.1016/0006-8993(92)90805-J
59.
Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T: Psychosis pathways converge via D2High dopamine receptors. Synapse 2006;60:319-346.
[PubMed]
https://doi.org/10.1002/syn.20303
60.
Seeman P, Guan HC: Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur J Pharmacol 2007;557:151-153.
[PubMed]
https://doi.org/10.1016/j.ejphar.2006.11.016
61.
Seeman P: Dopamine D2High receptors moderately elevated by sertindole. Synapse 2008;62:389-393.
[PubMed]
https://doi.org/10.1002/syn.20498
62.
Seeman P: Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole. Synapse 2008;62:902-908.
[PubMed]
https://doi.org/10.1002/syn.20557
63.
Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S: The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009;34:1078-1086.
[PubMed]
https://doi.org/10.1038/npp.2008.199
64.
Seeman P: Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. Synapse 2012;66:88-93.
[PubMed]
https://doi.org/10.1002/syn.20987
65.
Cho D, Zheng M, Min C, Ma L, Kurose H, Park JH, Kim KM: Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D2 receptors. Mol Endocrinol 2010;24:574-586.
[PubMed]
https://doi.org/10.1210/me.2009-0369
66.
Rogue P, Hanauer A, Zwiller J, Malviya AN, Vincendon G: Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur J Pharmacol 1991;207:165-168.
[PubMed]
https://doi.org/10.1016/0922-4106(91)90092-V
67.
Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M: G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis. J Psychopharmacol 2015;29:1308-1313.
[PubMed]
https://doi.org/10.1177/0269881115593903
68.
Oda Y, Kanahara N, Iyo M: Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci 2015;16:30144-30163.
[PubMed]
https://doi.org/10.3390/ijms161226228
69.
Chouinard G, Sultan S: Treatment of neuroleptic-induced supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. Psychopharmacol Bull 1990;26:337-341.
70.
Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
[PubMed]
71.
Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8:21S-26S.
[PubMed]
72.
Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull 1986;22:891-896.
[PubMed]
73.
Chouinard G, Miller R: A Rating Scale for Psychotic Symptoms (RSPS) part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations). Schizophr Res 1999;38:101-122.
[PubMed]
https://doi.org/10.1016/S0920-9964(99)00012-2
74.
Chouinard G, Miller R: A Rating Scale for Psychotic Symptoms (RSPS): part II: subscale 2: distraction symptoms (catatonia and passivity experiences subscale 3: delusions and semi-structured interview (SSCI-RSPS). Schizophr Res 1999;38:123-150.
[PubMed]
https://doi.org/10.1016/S0920-9964(99)00013-4
75.
Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA: Clozapine eligibility: the effect of stringent criteria on ethnic, gender and age subgroups of schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1341-1352.
[PubMed]
https://doi.org/10.1016/S0278-5846(96)00130-3
76.
Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA: Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995;46:801-806.
[PubMed]
77.
Carpenter WT Jr, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583.
[PubMed]
78.
Kolalowska T: Brief Psychiatric Rating Scale. Glossaries and Rating Instructions. Oxford, Oxford University, 1976.
79.
Inada T: Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients (in Japanese). Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16:181-185.
[PubMed]
80.
Inada T, Inagaki A: Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015;69:440-447.
[PubMed]
https://doi.org/10.1111/pcn.12275
81.
Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
[PubMed]
https://doi.org/10.1016/j.schres.2005.02.013
82.
Chouinard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
83.
Overall J, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
84.
Kimura H, Kanahara N, Sasaki T, Komatsu N, Ishige M, Muneoka K, Ino H, Yoshimura K, Yamanaka H, Suzuki T, Komatsu H, Watanabe H, Shimizu E, Iyo M: Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. J Psychopharmacol 2016;30:795-802.
[PubMed]
https://doi.org/10.1177/0269881116655978
85.
Wing J, Cooper JE, Sartorius N: Measurement and Classification of Psychiatric Symptoms. Cambridge, Cambridge University Press, 1974.
86.
Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. Washington, US Department of Health, Education, and Welfare, 1976.
87.
Brown GW, Harris T: Social Origins of Depression: A Study of Psychiatric Disorder in Women. London, Tavistock, 1978.
88.
Fallon P: The role of intrusive and other recent life events on symptomatology in relapses of schizophrenia: a community nursing investigation. J Psychiatr Ment Health Nurs 2009;16:685-693.
[PubMed]
https://doi.org/10.1111/j.1365-2850.2009.01451.x
89.
Chouinard G: Rebound anxiety: incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monograph 1986;4:12-16.
90.
Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(suppl 5):7-12.
[PubMed]
https://doi.org/10.1001/jama.277.4.301
91.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015;84:72-81.
[PubMed]
https://doi.org/10.1159/000370338
92.
Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC: Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006;67(suppl 4):27-30.
[PubMed]
93.
Tranter R, Healy D: Neuroleptic discontinuation syndromes. J Psychopharmacol 1998;12:401-406.
[PubMed]
https://doi.org/10.1177/026988119801200412
94.
Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, Kuhn KU, Volz HP, Riedel M: Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013;27:545-572.
[PubMed]
https://doi.org/10.1007/s40263-013-0079-5
95.
Brower KJ: Alcohol's effects on sleep in alcoholics. Alcohol Res Health 2001;25:110-125.
[PubMed]
96.
Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE: Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001;141:148-153.
[PubMed]
https://doi.org/10.1067/mhj.2001.111547
97.
Stevenson E, Schembri F, Green DM, Burns JD: Serotonin syndrome associated with clozapine withdrawal. JAMA Neurol 2013;70:1054-1055.
[PubMed]
https://doi.org/10.1001/jamaneurol.2013.95
98.
Hu WW, Fang Q, Xu ZH, Yan HJ, He P, Zhong K, Fan YY, Yang Y, Zhang XN, Zhang CY, Ohtsu H, Xu TL, Chen Z: Chronic H1-antihistamine treatment increases seizure susceptibility after withdrawal by impairing glutamine synthetase. CNS Neurosci Ther 2012;18:683-690.
[PubMed]
https://doi.org/10.1111/j.1755-5949.2012.00356.x
99.
Nattel S, Rangno RE, Van Loon G: Mechanism of propranolol withdrawal phenomena. Circulation 1979;59:1158-1164.
[PubMed]
https://doi.org/10.1161/01.CIR.59.6.1158
100.
Luchins DJ, Freed WJ, Wyatt RJ: The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980;137:1395-1398.
[PubMed]
101.
Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR: Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595.
[PubMed]
https://doi.org/10.1093/schbul/22.4.591
102.
Houston MC, Hodge R: Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116:515-523.
[PubMed]
https://doi.org/10.1016/0002-8703(88)90627-8
103.
Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 1984;141:848-852.
[PubMed]
104.
Kales A, Bixler EO, Tan TL, Scharf MB, Kales JD: Chronic hypnotic-drug use. Ineffectiveness, drug-withdrawal insomnia, and dependence. JAMA 1974;227:513-517.
[PubMed]
https://doi.org/10.1001/jama.1974.03230180011004
105.
Kales A, Scharf MB, Kales JD: Rebound insomnia: a new clinical syndrome. Science 1978;201:1039-1041.
[PubMed]
https://doi.org/10.1126/science.684426
106.
Oswald I, Priest RG: Five weeks to escape the sleeping-pill habit. Br Med J 1965;2:1093-1095.
[PubMed]
107.
Kales A, Preston TA, Tan TL, Allen C: Hypnotics and altered sleep-dream patterns. I. All-night EEG studies of glutethimide, methyprylon, and pentobarbital. Arch Gen Psychiatry 1970;23:211-218.
[PubMed]
https://doi.org/10.1001/archpsyc.1970.01750030019004
108.
Miller RR, Olson HG, Amsterdam EA, Mason DT: Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975;293:416-418.
[PubMed]
https://doi.org/10.1056/NEJM197508282930902
109.
Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006;13:e69-e74.
[PubMed]
110.
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
[PubMed]
https://doi.org/10.1016/S0006-3223(98)00126-7
111.
Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368.
[PubMed]
112.
Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G: Hypnotics and triazolobenzodiazepines - best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom 2015;84:273-283.
[PubMed]
https://doi.org/10.1159/000434755
113.
Mendelson JH, Mello NK: Management of cocaine abuse and dependence. N Engl J Med 1996;334:965-972.
[PubMed]
https://doi.org/10.1056/NEJM199604113341507
114.
Kosten TR, O'Connor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786-1795.
[PubMed]
https://doi.org/10.1056/NEJM200307243490420
115.
Markowitz JS, Brown CS, Moore TR: Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85.
[PubMed]
https://doi.org/10.1345/aph.17215
116.
Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
[PubMed]
https://doi.org/10.1176/appi.ajp.158.3.360
117.
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-320.
[PubMed]
https://doi.org/10.1017/S1461145709990423
118.
Sanford M: Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 2011;25:803-813.
[PubMed]
https://doi.org/10.2165/11207280-000000000-00000
119.
Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S: Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008;69:81-86.
[PubMed]
120.
Seeman P, Tallerico T: Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-884.
[PubMed]
https://doi.org/10.1176/ajp.156.6.876
121.
Burki HR: Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology (Berl) 1986;89:77-84.
[PubMed]
https://doi.org/10.1007/BF00175194
122.
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559.
[PubMed]
https://doi.org/10.1001/archpsyc.57.6.553
123.
Rangno RE, Nattel S, Lutterodt A: Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. Am J Cardiol 1982;49:828-833.
[PubMed]
https://doi.org/10.1016/0002-9149(82)91965-8
124.
Rangno RE, Langlois S: Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Br J Clin Pharmacol 1982;13:345S-351S.
[PubMed]
125.
Gilligan DM, Chan WL, Stewart R, Oakley CM: Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991;68:766-772.
[PubMed]
https://doi.org/10.1016/0002-9149(91)90651-Z
126.
Ashton H: Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 1991;8:19-28.
[PubMed]
https://doi.org/10.1016/0740-5472(91)90023-4
127.
Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007;10:835-838.
[PubMed]
128.
Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012;81:386-388.
[PubMed]
https://doi.org/10.1159/000341178
129.
Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014;83:247-248.
[PubMed]
https://doi.org/10.1159/000362317
130.
Shoenberger D: Discontinuing paroxetine: a personal account. Psychother Psychosom 2002;71:237-238.
[PubMed]
https://doi.org/10.1159/000063650
131.
Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia. Am J Psychiatry 1979;136:79-82.
[PubMed]
132.
Christensen AV, Fjalland B, Nielsen IM: On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology (Berl) 1976;48:1-6.
[PubMed]
https://doi.org/10.1007/BF00423298
133.
Chouinard G, Jones BD: Early onset of tardive dyskinesia: case report. Am J Psychiatry 1979;136:1323-1324.
[PubMed]
134.
Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J 1982;126:821-822, 827.
[PubMed]
135.
Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711-717.
[PubMed]
136.
Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna) 2000;107:295-302.
[PubMed]
https://doi.org/10.1007/s007020050024
137.
Brunelin J, d'Amato T, Van Os J, Costes N, Suaud Chagny MF, Saoud M: Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 2010;181:130-135.
[PubMed]
https://doi.org/10.1016/j.pscychresns.2009.10.002
138.
Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
[PubMed]
https://doi.org/10.1176/appi.ajp.157.4.514
139.
Gardos G, Cole JO, Tarsy D: Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135:1321-1324.
[PubMed]
140.
Kimura H, Kanahara N, Watanabe H, Iyo M: Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 2013;145:130-131.
[PubMed]
https://doi.org/10.1016/j.schres.2013.01.008
141.
Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F: Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 2000;150:422-429.
[PubMed]
142.
Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S: Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006;31:1854-1863.
[PubMed]
https://doi.org/10.1038/sj.npp.1300983
143.
Van Putten T, May RP: “Akinetic depression” in schizophrenia. Arch Gen Psychiatry 1978;35:1101-1107.
[PubMed]
https://doi.org/10.1001/archpsyc.1978.01770330075006
144.
Rifkin A, Quitkin F, Klein DF: Akinesia: a poorly recognized drug-induced extrapyramydal behavioral disorder. Arch Gen Psychiatry 1975;32:672-674.
https://doi.org/10.1001/archpsyc.1975.01760230138011
145.
Voruganti LP, Awad AG: Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry 2004;49:285-289.
[PubMed]
https://doi.org/10.1177/070674370404900502
146.
Margolese HC, Chouinard G, Walters Larach V, Beauclair L: Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatr Belg 2001;101:128-144.
147.
Van Putten T, Mutalipassi LR, Malkin MD: Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974;30:102-105.
[PubMed]
https://doi.org/10.1001/archpsyc.1974.01760070080012
148.
Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 2012;134:219-225.
[PubMed]
https://doi.org/10.1016/j.schres.2011.11.021
149.
Valenti O, Cifelli P, Gill KM, Grace AA: Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci 2011;31:12330-12338.
[PubMed]
https://doi.org/10.1523/JNEUROSCI.2808-11.2011
150.
Benet LZ, Zia-Amirhosseini P: Basic principles of pharmacokinetics. Toxicol Pathol 1995;23:115-123.
[PubMed]
https://doi.org/10.1177/019262339502300203
151.
Sheehan JJ, Reilly KR, Fu DJ, Alphs L: Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci 2012;9:17-23.
[PubMed]
152.
Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980;5:246-262.
[PubMed]
https://doi.org/10.2165/00003088-198005030-00004
153.
Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM: The pharmacokinetics of second-generation long-acting injectable antipsychotics: limitations of monograph values. CNS Drugs 2015;29:975-983.
[PubMed]
https://doi.org/10.1007/s40263-015-0295-2
154.
Ericson H, Radesater AC, Servin E, Magnusson O, Mohringe B: Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat. Pharmacol Toxicol 1996;79:277-286.
[PubMed]
https://doi.org/10.1111/j.1600-0773.1996.tb00009.x
155.
Smith RC, Davis JM: Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Psychopharmacol Commun 1975;1:285-293.
[PubMed]
156.
Fukushiro DF, Carvalho Rde C, Ricardo VP, Alvarez Jdo N, Ribeiro LT, Frussa-Filho R: Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. Brain Res Bull 2008;77:124-128.
[PubMed]
https://doi.org/10.1016/j.brainresbull.2008.05.004
157.
Carvalho RC, Fukushiro DF, Helfer DC, Callegaro-Filho D, Trombin TF, Zanlorenci LH, Sanday L, Silva RH, Frussa-Filho R: Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Addict Biol 2009;14:283-293.
[PubMed]
https://doi.org/10.1111/j.1369-1600.2008.00145.x
158.
Montanaro N, Dall'Olio R, Gandolfi O, Vaccheri A: Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol. Eur J Pharmacol 1982;81:1-9.
[PubMed]
https://doi.org/10.1016/0014-2999(82)90595-7
159.
Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN: Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003;305:625-631.
[PubMed]
https://doi.org/10.1124/jpet.102.046987
160.
McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ: Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 1980;137:510-517.
[PubMed]
https://doi.org/10.1192/bjp.137.6.510
161.
Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S: “Extended” antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:1042-1048.
[PubMed]
https://doi.org/10.4088/JCP.09m05866yel
162.
Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H: Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: a single-blind, randomized, controlled study. Schizophr Res 2015;164:149-154.
[PubMed]
https://doi.org/10.1016/j.schres.2015.03.025
163.
Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L: D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152:173-178.
[PubMed]
164.
Uchida H, Suzuki T: Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol 2014;34:728-735.
[PubMed]
https://doi.org/10.1097/JCP.0000000000000065
165.
Samaha AN: Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2014;52:9-16.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2013.06.008
166.
Samaha AN, Potvin S: Drugs of abuse and psychiatric disorders: neurobiological and clinical aspects. Prog Neuropsychopharmacol Biol Psychiatry 2014;52:1-3.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2014.03.012
167.
Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
[PubMed]
https://doi.org/10.1176/appi.ajp.161.3.414
168.
Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY: ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 2005;183:144-153.
[PubMed]
https://doi.org/10.1007/s00213-005-0170-9
169.
Chouinard G: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15:36S-44S.
[PubMed]
https://doi.org/10.1097/00004714-199502001-00007
170.
Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67.
171.
Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719.
[PubMed]
https://doi.org/10.1038/261717a0
172.
Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010;4:56-73.
[PubMed]
https://doi.org/10.3371/CSRP.4.1.5
173.
Goldstein J, Macfadden W: Reply to article by Margolese and associates on tolerance and rebound during maintenance with quetiapine. J Clin Psychopharmacol 2004;24:102-103; author reply 103-104.
[PubMed]
https://doi.org/10.1097/01.jcp.0000106231.36344.f8
174.
Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
[PubMed]
https://doi.org/10.1001/archpsyc.60.1.82
175.
Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R: Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:867-872.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2007.01.025
176.
Creese I, Snyder SH: Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol 1980;24:89-94.
[PubMed]
177.
Severson JA, Robinson HE, Simpson GM: Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology (Berl) 1984;84:115-119.
[PubMed]
https://doi.org/10.1007/BF00432038
178.
Seeman P, Corbett R, Van Tol HH: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997;16:93-110; discussion 111-135.
[PubMed]
https://doi.org/10.1016/S0893-133X(96)00187-X
179.
Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-392.
[PubMed]
180.
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB: Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007;320:1-13.
[PubMed]
https://doi.org/10.1124/jpet.106.104463
181.
de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 2015;29:773-799.
[PubMed]
https://doi.org/10.1007/s40263-015-0278-3
182.
Urban JD, Vargas GA, von Zastrow M, Mailman RB: Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32:67-77.
[PubMed]
https://doi.org/10.1038/sj.npp.1301071
183.
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389.
[PubMed]
https://doi.org/10.1124/jpet.102.033175
184.
Di Lorenzo R, Amoretti A, Forghieri M, Fiorini F, Genedani S, Rigatelli M: Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007;15:569-575.
[PubMed]
https://doi.org/10.1037/1064-1297.15.6.569
185.
Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136.
[PubMed]
https://doi.org/10.1016/S0920-9964(03)00050-1
186.
Gorwood P: Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 2006;16(suppl 3): S156-S162.
[PubMed]
https://doi.org/10.1016/j.euroneuro.2006.06.002
187.
Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, Uchimura N, Nishimura R, Shimizu N, Group AS: Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res 2015;161:421-428.
[PubMed]
https://doi.org/10.1016/j.schres.2014.12.013
188.
Sultan S, Chouinard G, Beaudry P: Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:431-438.
[PubMed]
https://doi.org/10.1016/0278-5846(90)90031-B
189.
Goddard GV, McIntyre DC, Leech CK: A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295-330.
[PubMed]
https://doi.org/10.1016/0014-4886(69)90128-9
190.
Moskovitz C, Moses H 3rd, Klawans HL: Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
[PubMed]
191.
Post RM, Kopanda RT, Black KE: Progressive effects of cocaine on behavior and central amine metabolism in rhesus monkeys: relationship to kindling and psychosis. Biol Psychiatry 1976;11:403-419.
[PubMed]
192.
Chouinard G, Beauclair L, Belanger MC: Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998;43:305.
[PubMed]
193.
Kolivakis TT, Beauclair L, Margolese HC, Chouinard G: Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can J Psychiatry 2004;49:280.
[PubMed]
https://doi.org/10.1177/070674370404900411
194.
Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, Miller R: Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1129-1141.
[PubMed]
https://doi.org/10.1016/0278-5846(94)90116-3
195.
Kristensen D, Hageman I, Bauer J, Jorgensen MB, Correll CU: Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J ECT 2013;29:271-276.
[PubMed]
https://doi.org/10.1097/YCT.0b013e31828b34f6
196.
McGarvey KA, Zis AP, Brown EE, Nomikos GG, Fibiger HC: ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry 1993;34:152-157.
[PubMed]
https://doi.org/10.1016/0006-3223(93)90385-Q
197.
Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M: Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol 2017;32:169-173.
[PubMed]
https://doi.org/10.1097/YIC.0000000000000160
198.
Louzã MR, Bassitt DP: Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. J Clin Psychopharmacol 2005;25:180-182.
[PubMed]
https://doi.org/10.1097/01.jcp.0000155823.59585.88
199.
Weber J, McCormack PL: Asenapine. CNS Drugs 2009;23:781-792.
[PubMed]
https://doi.org/10.2165/1120086-000000000-00000
200.
Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73.
[PubMed]
https://doi.org/10.1177/0269881107082944
201.
Rajkumar RP: Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder. Case Rep Psychiatry 2014;2014:215732.
[PubMed]
https://doi.org/10.1155/2014/215732
202.
Matteo P, Mula M, Basaglia C, Favaretto E, Schwitzer J: Asenapine after clozapine: is possible? Eur Psychiatry 2013;28:1.
https://doi.org/10.1016/S0924-9338(13)77392-9
203.
UpToDate: Asenapine: Drug Information. Alphen aan den Rijn, Wolters Kluwer, 2017.
204.
Kokare CK, Tagalpallewar AA, Aragade PS, Bagul US, Bacchav RK, Nanjwade BK: Formulation, evaluation and optimization of asenapine maleate fast mouth dissolving film. J Pharm Sci Pharmacol 2015;2:194-207.
https://doi.org/10.1166/jpsp.2015.1062
205.
Huang M, Kwon S, Oyamada Y, Rajagopal L, Miyauchi M, Meltzer HY: Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav 2015;138:49-57.
[PubMed]
https://doi.org/10.1016/j.pbb.2015.09.011
206.
Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY: Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 2014;128:938-949.
[PubMed]
https://doi.org/10.1111/jnc.12512
207.
Tachibana M, Niitsu T, Watanabe M, Hashimoto T, Kanahara N, Ishikawa M, Iyo M: Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: a retrospective analysis. Asian J Psychiatr 2016;24:28-32.
[PubMed]
https://doi.org/10.1016/j.ajp.2016.08.014
208.
Inoue T, Osada K, Tagawa M, Ogawa Y, Haga T, Sogame Y, Hashizume T, Watanabe T, Taguchi A, Katsumata T, Yabuki M, Yamaguchi N: Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:156-162.
[PubMed]
https://doi.org/10.1016/j.pnpbp.2012.06.005
209.
Chouinard G, Annable L, Ross-Chouinard A, Holobow N: A ten-year follow-up of supersensitivity psychosis. Biol Psychiatry 1990;27:110A.
https://doi.org/10.1016/0006-3223(90)90231-P
210.
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547.
[PubMed]
https://doi.org/10.1177/070674370505000907
211.
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714.
[PubMed]
https://doi.org/10.1177/070674370505001110
212.
de Montigny C, Chouinard G, Annable L: Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl) 1979;65:219-223.
[PubMed]
https://doi.org/10.1007/BF00492207
213.
Chouinard G, De Montigny C, Annable L: Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry 1979;136:228-229.
[PubMed]
https://doi.org/10.1176/ajp.136.2.228
214.
Dyer C: European court upholds UK ban on Halcion. BMJ 1999;318:418.
[PubMed]
https://doi.org/10.1136/bmj.318.7181.418a
215.
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-953.
[PubMed]
https://doi.org/10.1176/appi.ajp.162.5.947
216.
Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207.
[PubMed]
https://doi.org/10.1186/cvm-2-5-205
217.
Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, Ongur D: Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res 2016;237:304-310.
[PubMed]
https://doi.org/10.1016/j.psychres.2016.01.024
218.
McGuinness SM, Johansson R, Lundstrom J, Ross D: Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia. Chem Biol Interact 1999;121:253-265.
[PubMed]
https://doi.org/10.1016/S0009-2797(99)00105-2
219.
Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782.
[PubMed]
https://doi.org/10.1176/appi.ajp.158.11.1774
220.
Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
[PubMed]
https://doi.org/10.1056/NEJMra032426
221.
Isbister GK, Murray L, John S, Hackett LP, Haider T, O'Mullane P, Gosselin S, Daly F: Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust 2006;184:354-356.
[PubMed]
222.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
[PubMed]
https://doi.org/10.1016/S0140-6736(13)60733-3
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.